Lenalidomide Sun Pharma (Lenalidomide)

Lenalidomide exerts its effect by binding to the cereblon protein, part of an E3 ubiquitin ligase complex. This interaction modifies the degradation of specific transcription factors, leading to enhanced immune cell activity, inhibition of new blood‑vessel formation, and induction of programmed cell death in malignant plasma cells.

The dosage of Lenalidomide Sun Pharma is individualized by the prescribing clinician based on the specific indication, disease severity, renal function, and patient tolerance. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Lenalidomide is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Lenalidomide belongs to the immunomodulatory drug class and differs from proteasome inhibitors or monoclonal antibodies by primarily enhancing immune response and inhibiting angiogenesis. Clinical studies show it can be effective as a single agent or in combination regimens, offering an alternative mechanism of action compared with other standard myeloma therapies.

Lenalidomide Sun Pharma should be stored at temperatures below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and ensure the packaging remains sealed until use to maintain stability.

Lenalidomide Sun Pharma is taken orally, usually with or without food, as directed by the prescribing physician. The tablets (or capsules, depending on the supplied form) should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include the development of venous thromboembolism, severe skin reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, significant liver injury, and life‑threatening infections. Patients should be monitored closely for these events, and therapy should be stopped immediately if any serious adverse reaction occurs.

Lenalidomide Sun Pharma should not be used by individuals who are pregnant, have uncontrolled infections, have a known hypersensitivity to lenalidomide or any excipients, or have severe renal or hepatic impairment without appropriate dose adjustment. The drug is also contraindicated in patients with a history of thromboembolic events unless prophylactic anticoagulation is in place.